Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440144 | 0.94 | MAPT (0.60) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL4297250 | 0.91 | MAPT (0.53) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL12005391 | 0.91 | MAPT (0.53) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL25046030 | 0.91 | MAPT (0.53) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL16580726 | 0.88 | SIRT6 (0.56) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL30878667 | 0.86 | MEN1 (0.59) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL14167563 | 0.84 | MAPT (0.59) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL9451699 | 0.83 | SIRT6 (0.51) | MAPTALDH1A1SIRT6MEN1KMT2A | |
| SCHEMBL3440420 | 0.82 | MAPT (0.54) | MAPTALDH1A1MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL7289172 | 0.82 | MAPT (0.56) | MAPTALDH1A1SIRT6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| CN-112142748-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-4008719-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-1942464-A | Novel piperidine substituted diaminothiazoles | HOFFMANN LA ROCHE (CH) | 2007-04-04 | — | — | CN | disclosed |
| EP-1740576-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103034-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239843-A1 | Diaminothiazoles | DING QINGJIE | 2005-10-27 | — | — | US | disclosed |
| CN-1433417-A | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239843-A1 | Diaminothiazoles | CDK4, CDK2, CDK1 | MAPT 1975/4885ALDH1A1 762/4885SIRT6 711/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | MAPT 4708/4885ALDH1A1 999/4885SIRT6 4605/4885 |
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | WEE1, WEE2, WASF2 | MAPT 4504/4885ALDH1A1 2757/4885SIRT6 1389/4885 |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | WEE1, WEE2, RCE1 | MAPT 25/4885ALDH1A1 3670/4885SIRT6 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.